Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.

Source: MarketWatch · 2026-10-29 12:03 UTC

Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.

The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.

Read the full story at MarketWatch

Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.

More from the world desk

Vulnerable at risk as 'life-saving' drug needle site closes BBC Health
Mastercard Non-GAAP EPS of $5.31 beats by $0.14, revenue of $9.8B beats by $140M Seeking Alpha
Hegseth reportedly fires U.S. top military planner as Trump downplays Iran peace talks CNBC Markets
Insperity Non-GAAP EPS of $0.22 beats by $0.01, revenue of $1.65B beats by $10M Seeking Alpha
Silicom beats top-line and bottom-line estimates; gives Q4 and raises FY26 outlook Seeking Alpha
Sonic Automotive declares $0.41 dividend Seeking Alpha

GodsView is a live globe of public flights, ships, wildfires, and earthquakes, plus a world news desk. Home · World desk · Globe · Blog · How to use · RSS · llms.txt